Loading ...
Sorry, an error occurred while loading the content.

Article on PEG Interferon-Marty

Expand Messages
  • 2byteme@bellsouth.net
    Chronic Hepatitis C More Responsive to Peginterferon Than Interferon WESTPORT, CT (Reuters Health) Dec 06 - For patients with chronic hepatitis C with or
    Message 1 of 1 , Dec 10, 2000
    • 0 Attachment
      Chronic Hepatitis C More Responsive
      to Peginterferon Than Interferon


      WESTPORT, CT (Reuters Health) Dec 06 - For patients with
      chronic hepatitis C with or without cirrhosis, a regimen of
      peginterferon alpha-2a is significantly more effective than
      treatment with interferon alpha-2a, according to two reports in
      the New England Journal of Medicine for December 7.

      During a 48-week trial, Dr. Stefan Zeuzem from the Klinikum
      der Johann Wolfgang Goethe Universitat, Frankfurt, Germany,
      and colleagues randomly assigned 267 patients with chronic
      hepatitis C to receive 180 mcg of peginterferon alpha-2a once a
      week for 48 weeks. They assigned 264 patients to receive 6
      million units of interferon alpha-2a three times a week for 12
      weeks, followed by 3 million units three times a week for 36
      weeks.

      In an intention-to-treat analysis, Dr. Zeuzem's team found that at
      48 weeks, 69% of the patients taking peginterferon had a high
      rate of virologic response compared with 28% of the patients
      taking interferon. Analysis at 72 weeks showed that a high
      virologic response was present in 39% of the patients receiving
      peginterferon and in 19% of those receiving interferon.

      The investigators also report that "sustained normalization of
      serum alanine aminotransferase concentrations at week 72 was
      also more common in the peginterferon group than in the
      interferon group (45% vs. 25%)."

      In the second study, Dr. E. Jenny Heathcote, from Toronto
      Western Hospital, Ontario, Canada, and colleagues randomized
      271 patients with hepatitis C and cirrhosis or bridging fibrosis to
      receive 3 million units of interferon alpha-2a three times a week
      or 90 or 180 mcg of peginterferon alpha-2a once a week. Both
      regimens lasted 48 weeks.

      At 72 weeks, the investigators found that hepatitis C RNA was
      undetectable in 30% of the patients who received 180 mcg of
      peginterferon, compared with 15% of the patients who received
      90 mcg of peginterferon, and 8% of the patients who were given
      interferon.

      Serum alanine aminotransferase concentrations were normal at
      72 weeks in 34% of the peginterferon 180 mcg group,
      compared with 20% of the peginterferon 90 mcg group and 15%
      of the interferon group.

      In a subgroup of 184 patients for whom there were paired liver
      biopsies, Dr. Heathcote and colleagues noted that at week 72
      the rate of histologic response was 31% for those receiving 180
      mcg of peginterferon, 44% for patients receiving 90 mcg of
      peginterferon, and 54% for those receiving interferon.

      In a related editorial, Dr. Daniel F. Schafer and Dr. Michael F.
      Sorrell from the University of Nebraska Medical Center,
      Omaha, say that although peginterferon alpha-2a is not yet
      approved for use in the US, "treatment with peginterferon
      alpha-2a in combination with ribavirin is the next obvious step in
      the treatment of chronic hepatitis C virus infection."

      N Engl Med 2000;343:1666-1680,1723-1724.
    Your message has been successfully submitted and would be delivered to recipients shortly.